Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Tóm tắt
Từ khóa
Tài liệu tham khảo
Rosenberg, S.A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18, 175–182 (1997).
Steinman, R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271–296(1991).
Flamand, V. et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 24, 605–610 (1994).
Mayordomo, J.I. et al. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nature Med. 1, 1297–1302(1995).
Mayordomo, J.I. et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183, 1357–1365 (1996).
Paglia, P. et al. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183, 317–322 (1996).
Porgador, A. et al. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156, 2918–2926 (1996).
Shimizu, J. et al. Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells. J. Immunol. 142, 1053–1059 (1989).
Zitvogel, L. et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1 -associated cytokines. Exp. Med. 183, 87–97 (1996).
Celluzzi, C. et al. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. 183, 283–287 (1996).
Marchand, M. et al. Tumor regression responses in melanoma patients with a peptide encoded by gene MAGE-3. Int. J. Cancer 63, 883–885 (1995).
Jäger, E. et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer 66, 162–169 (1996).
Cormier, J.N. et al. Enhancement of cellular immunity in melanoma patient immunized with a peptide from MART-1/Melan-A. Cancer J. Sci. Am. 3, 37–44 (1997).
Grabbe, S. et al. Dendritic cells as initiators of tumor immune responses—a possible strategy for tumor immunotherapy? Immunol. Today 16, 117–121 (1995).
Peters, J.H. et al. Dendritic cells: from ontogenetic orphans to myelomonocytic descendants. Immunol. Today 17, 273–278 (1996).
Caux, C. er al. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 360, 258–261 (1992).
Romani, N. et al. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180, 83–93 (1994).
Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor-alpha. J. Exp. Med 179, 1109–111 (1994).
Bennett, S.R.M. et al. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ help. J. Exp. Med. 186, 65–70 (1997).
Hsu, F.J. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2, 52–58 (1996).
Mukherji, B. et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad Sci. USA 92, 8078–802 (1995).